Change-Plane Analysis for Subgroup Detection and Sample Size Calculation.
Ontology highlight
ABSTRACT:
SUBMITTER: Fan A
PROVIDER: S-EPMC5553128 | biostudies-other | 2017
REPOSITORIES: biostudies-other
Similar Datasets
Project description:In this paper, we propose a testing procedure for detecting and estimating the subgroup with an enhanced treatment effect in survival data analysis. Here, we consider a new proportional hazard model that includes a nonparametric component for the covariate effect in the control group and a subgroup-treatment-interaction effect defined by a change plane. We develop a score-type test for detecting the existence of the subgroup, which is doubly robust against misspecification of the baseline effect model or the propensity score but not both under mild assumptions for censoring. When the null hypothesis of no subgroup is rejected, the change-plane parameters that define the subgroup can be estimated on the basis of supremum of the normalized score statistic. The asymptotic distributions of the proposed test statistic under the null and local alternative hypotheses are established. On the basis of established asymptotic distributions, we further propose a sample size calculation formula for detecting a given subgroup effect and derive a numerical algorithm for implementing the sample size calculation in clinical trial designs. The performance of the proposed approach is evaluated by simulation studies. An application to an AIDS clinical trial data is also given for illustration.
| S-EPMC5698151 | biostudies-literature
Project description:Sample size calculations are an essential component of the design and evaluation of scientific studies. However, there is a lack of clear guidance for determining the sample size needed for phylogenetic studies, which are becoming an essential part of studying pathogen transmission. We introduce a statistical framework for determining the number of true infector-infectee transmission pairs identified by a phylogenetic study, given the size and population coverage of that study. We then show how characteristics of the criteria used to determine linkage and aspects of the study design can influence our ability to correctly identify transmission links, in sometimes counterintuitive ways. We test the overall approach using outbreak simulations and provide guidance for calculating the sensitivity and specificity of the linkage criteria, the key inputs to our approach. The framework is freely available as the R package phylosamp, and is broadly applicable to designing and evaluating a wide array of pathogen phylogenetic studies.
| S-EPMC8284614 | biostudies-literature
Project description:BackgroundMulti-centre randomized controlled clinical trials play an important role in modern evidence-based medicine. Advantages of collecting data from more than one site are numerous, including accelerated recruitment and increased generalisability of results. Mixed models can be applied to account for potential clustering in the data, in particular when many small centres contribute patients to the study. Previously proposed methods on sample size calculation for mixed models only considered balanced treatment allocations which is an unlikely outcome in practice if block randomisation with reasonable choices of block length is used.MethodsWe propose a sample size determination procedure for multi-centre trials comparing two treatment groups for a continuous outcome, modelling centre differences using random effects and allowing for arbitrary sample sizes. It is assumed that block randomisation with fixed block length is used at each study site for subject allocation. Simulations are used to assess operation characteristics such as power of the sample size approach. The proposed method is illustrated by an example in disease management systems.ResultsA sample size formula as well as a lower and upper boundary for the required overall sample size are given. We demonstrate the superiority of the new sample size formula over the conventional approach of ignoring the multi-centre structure and show the influence of parameters such as block length or centre heterogeneity. The application of the procedure on the example data shows that large blocks require larger sample sizes, if centre heterogeneity is present.ConclusionUnbalanced treatment allocation can result in substantial power loss when centre heterogeneity is present but not considered at the planning stage. When only few patients by centre will be recruited, one has to weigh the risk of imbalance between treatment groups due to large blocks and the risk of unblinding due to small blocks. The proposed approach should be considered when planning multi-centre trials.
| S-EPMC6267841 | biostudies-literature
Project description:Since the era of evidence-based medicine, it has become a matter of course to use statistics to create objective evidence in clinical research. As an extension of this, it has become essential in clinical research to calculate the correct sample size to demonstrate a clinically significant difference before starting the study. Also, because sample size calculation methods vary from study design to study design, there is no formula for sample size calculation that applies to all designs. It is very important for us to understand this. In this review, each sample size calculation method suitable for various study designs was introduced using the R program (R Foundation for Statistical Computing). In order for clinical researchers to directly utilize it according to future research, we presented practice codes, output results, and interpretation of results for each situation.
| S-EPMC10020745 | biostudies-literature
Project description:We propose a multithreshold change plane regression model which naturally partitions the observed subjects into subgroups with different covariate effects. The underlying grouping variable is a linear function of observed covariates and thus multiple thresholds produce change planes in the covariate space. We contribute a novel two-stage estimation approach to determine the number of subgroups, the location of thresholds, and all other regression parameters. In the first stage we adopt a group selection principle to consistently identify the number of subgroups, while in the second stage change point locations and model parameter estimates are refined by a penalized induced smoothing technique. Our procedure allows sparse solutions for relatively moderate- or high-dimensional covariates. We further establish the asymptotic properties of our proposed estimators under appropriate technical conditions. We evaluate the performance of the proposed methods by simulation studies and provide illustrations using two medical data examples. Our proposal for subgroup identification may lead to an immediate application in personalized medicine.
| S-EPMC8180507 | biostudies-literature
Project description:The case-cohort (CC) study design usually has been used for risk factor assessment in epidemiologic studies or disease prevention trials for rare diseases. The sample size/power calculation for a stratified CC (SCC) design has not been addressed before. This article derives such result based on a stratified test statistic. Simulation studies show that the proposed test for the SCC design utilizing small sub-cohort sampling fractions is valid and efficient for situations where the disease rate is low. Furthermore, optimization of sampling in the SCC design is discussed and compared with proportional and balanced sampling techniques. An epidemiological study is provided to illustrate the sample size calculation under the SCC design.
| S-EPMC4159408 | biostudies-other
Project description:Sample size determination is an important issue in the experimental design of biomedical research. Because of the complexity of RNA-seq experiments, however, the field currently lacks a sample size method widely applicable to differential expression studies utilising RNA-seq technology. In this report, we propose several methods for sample size calculation for single-gene differential expression analysis of RNA-seq data under Poisson distribution. These methods are then extended to multiple genes, with consideration for addressing the multiple testing problem by controlling false discovery rate. Moreover, most of the proposed methods allow for closed-form sample size formulas with specification of the desired minimum fold change and minimum average read count, and thus are not computationally intensive. Simulation studies to evaluate the performance of the proposed sample size formulas are presented; the results indicate that our methods work well, with achievement of desired power. Finally, our sample size calculation methods are applied to three real RNA-seq data sets.
| S-EPMC3874726 | biostudies-literature
Project description:Genetic association studies, testing the relationship between genetic variants and disease status, are useful tools for identifying genes that grant susceptibility to complex disorders. In such studies, an inadequate sample size may provide unreliable results: a small sample is unable to accurately describe the population, whereas a large sample makes the study expensive and complex to run. However, in genetic association studies, the sample size calculation is often overlooked or inadequately assessed for the small number of parameters included. In light of this, herein we list and discuss the role of the statistical and genetic parameters to be considered in the sample size calculation, show examples reporting incorrect estimation and, by using a genetic software program, we provide a practical approach for the assessment of the adequate sample size in a hypothetical study aimed at analyzing a gene-disease association.
| S-EPMC9863799 | biostudies-literature
Project description:One of the main objectives of microarray analysis is to identify differentially expressed genes for different types of cells or treatments. Many statistical methods have been proposed to assess the treatment effects in microarray experiments.In this paper, we consider discovery of the genes that are differentially expressed among K (> 2) treatments when each set of K arrays consists of a block. In this case, the array data among K treatments tend to be correlated because of block effect. We propose to use the blocked one-way ANOVA F-statistic to test if each gene is differentially expressed among K treatments. The marginal p-values are calculated using a permutation method accounting for the block effect, adjusting for the multiplicity of the testing procedure by controlling the false discovery rate (FDR). We propose a sample size calculation method for microarray experiments with a blocked one-way design. With FDR level and effect sizes of genes specified, our formula provides a sample size for a given number of true discoveries.The calculated sample size is shown via simulations to provide an accurate number of true discoveries while controlling the FDR at the desired level.
| S-EPMC2702333 | biostudies-literature
Project description:BackgroundObservational burden of illness studies are used in pharmacoepidemiology to address a variety of objectives, including contextualizing the current treatment setting, identifying important treatment gaps, and providing estimates to parameterize economic models. Methodologies such as retrospective chart review may be utilized in settings for which existing datasets are not available or do not include sufficient clinical detail. While specifying the number of charts to be extracted and/or determining whether the number that can feasibly extracted will be clinically meaningful is an important study design consideration, there is a lack of rigorous methods available for sample size calculation in this setting. The objective of this study was to develop recommended sample size calculations for use in such studies.MethodsCalculations for identifying the optimal feasible sample size calculations were derived, for studies characterizing treatment patterns and medical costs, based on the ability to comprehensively observe treatments and maximize precision of resulting 95% confidence intervals. For cost outcomes, if the standard deviation is not known, the coefficient of variation cv can be used as an alternative. A case study of a chart review of advanced melanoma (MELODY) was used to characterize plausible values for cv in a real-world example.ResultsAcross sample sizes, any treatment given with greater than 1% frequency has a high likelihood of being observed. For a sample of size 200, and a treatment given to 5% of the population, the precision of a 95% confidence interval (CI) is expected to be ±0.03. For cost outcomes, for the median cv value observed in the MELODY study (0.72), a sample size of approximately 200 would be required to generate a 95% CI precise to within ±10% of the mean.ConclusionThis study presents a formal guidance on sample size calculations for retrospective burden of illness studies. The approach presented here is methodologically rigorous and designed for practical application in real-world retrospective chart review studies.
| S-EPMC6325730 | biostudies-literature